Analysts Set Masimo Co. (NASDAQ:MASI) PT at $163.67

Shares of Masimo Co. (NASDAQ:MASI) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $163.67.

A number of equities analysts recently commented on MASI shares. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price for the company in a report on Wednesday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Wells Fargo & Company increased their price objective on Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. BTIG Research increased their price objective on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Finally, Piper Sandler increased their price objective on Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th.

Hedge Funds Weigh In On Masimo

Several institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC increased its holdings in shares of Masimo by 41.2% during the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after acquiring an additional 1,970,883 shares in the last quarter. Farallon Capital Management LLC increased its holdings in shares of Masimo by 13.6% during the first quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock valued at $218,742,000 after acquiring an additional 177,914 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Masimo by 23.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock valued at $185,869,000 after buying an additional 262,370 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Masimo by 42.1% during the second quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock valued at $153,314,000 after buying an additional 360,497 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in shares of Masimo by 9.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider’s stock valued at $105,619,000 after buying an additional 70,440 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Stock Performance

NASDAQ:MASI opened at $160.15 on Tuesday. The firm has a market cap of $8.57 billion, a PE ratio of 110.38 and a beta of 0.97. Masimo has a fifty-two week low of $89.18 and a fifty-two week high of $173.90. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The business has a 50 day moving average price of $136.27 and a 200-day moving average price of $126.54.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 earnings per share. Equities research analysts predict that Masimo will post 4.04 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.